Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation

被引:55
|
作者
Colletier, PJ
Ashoori, F
Cowen, D
Meyn, RE
Tofilon, P
Meistrich, ME
Pollack, A
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA
关键词
prostate cancer; gene therapy; p53; radiotherapy; apoptosis;
D O I
10.1016/S0360-3016(00)01409-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose/Objective: The effect of adenoviral-mediated p53 transgene expression on the radiation response of two human prostate cancer cell lines, the p53(wild-type) LNCaP and p53(null) PC3 lines, was examined. The objective was to determine if this vector sensitizes cells to radiation independently of their p53 status. Methods and Materials: A recombinant adenovirus-5 vector (RPR/INGN 201, Introgen Therapeutics, Houston, TX) containing a CMV promoter and wild-type p53-cDNA (Ad5-p53) was used to facilitate p53 transgene expression. A multiplicity of infection (MOI) of 10-40 viral particles per cell was used, based on Ad5/CMV/lacz infection and staining for the beta -galactosidase reporter gene product. Clonogenic assays were performed to evaluate the degree of sensitization to radiation of viral-transduced cells compared with irradiated nontransduced controls. The relative efficacy of these treatments to induce apoptotic cell death was determined using the TUNEL assay. Results: The delivery of Ad5-p53 (10 MOI) reduced control plating efficiency from 36.5% to 0.86% in the LNCaP cell line and from 75.1% to 4.1% in the PC3 cell line. After correcting for the effect of Ad5-p53 on plating efficiency, the surviving fraction after 2 Gy (SF2) of gamma-irradiation was reduced over 2.5-fold, from 0.187 to 0.072, with transgene p53 expression in the LNCaP cell line. Surviving fraction after 4 Gy (SF4) was reduced over 4.5-fold, from 0.014 to 0.003, after Ad5-p53 treatment. In the PC3 cell line, Ad5-p53 (40 MOI) reduced SF2 over 19-fold from 0.708 to 0.367, and SF4 over 6-fold from 0.335 to 0.056. In both the LNCaP and PC3 cell lines, the combination of Ad5-p53 plus radiation (2 Gy) resulted in supra-additive apoptosis (similar to 20% for LNCaP and similar to 15% for PC3 at 50 MOI), above that seen from the addition of the controls; control vector Ad5-pA plus RT (0.15% for LNCaP and 1.44% for PC3), Ad5-p53 alone (28.6% for LNCaP and 21.7% for PC3), RT alone (0% for LNCaP and 0.23% for PC3), or Ad5-pb alone (0.1% for LNCaP and 0.29% for PC3). Conclusion: The clonogenic survival and apoptosis data demonstrate that p53 transgene expression sensitizes human prostate adenocarcinoma cells in vitro to irradiation. As this effect was observed in both the p53(wild-type) LNCaP and p53(null) PC3 lines, radiosensitization was independent of p53 status. (C) 2000 Elsevier Science Inc.
引用
收藏
页码:1507 / 1512
页数:6
相关论文
共 50 条
  • [21] Reconstitution of wild-type p53 through adenoviral-mediated gene transfer inhibits cellular proliferation and induces apoptosis in hepatoma cells
    Reiser, M
    Neumann, I
    Lauer, G
    Schmiegel, W
    Lau, JYN
    GASTROENTEROLOGY, 1997, 112 (04) : A1364 - A1364
  • [22] p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients
    Jean-Christophe Bourdon
    Marie P Khoury
    Alexandra Diot
    Lee Baker
    Kenneth Fernandes
    Mustapha Aoubala
    Philip Quinlan
    Colin A Purdie
    Lee B Jordan
    Anne-Catherine Prats
    David P Lane
    Alastair M Thompson
    Breast Cancer Research, 13
  • [23] TUMOR SUPPRESSOR P53 - ANALYSIS OF WILD-TYPE AND MUTANT P53 COMPLEXES
    MILNER, J
    MEDCALF, EA
    COOK, AC
    MOLECULAR AND CELLULAR BIOLOGY, 1991, 11 (01) : 12 - 19
  • [24] p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients
    Bourdon, Jean-Christophe
    Khoury, Marie P.
    Diot, Alexandra
    Baker, Lee
    Fernandes, Kenneth
    Aoubala, Mustapha
    Quinlan, Philip
    Purdie, Colin A.
    Jordan, Lee B.
    Prats, Anne-Catherine
    Lane, David P.
    Thompson, Alastair M.
    BREAST CANCER RESEARCH, 2011, 13 (01):
  • [25] WILD-TYPE ALTERNATIVELY SPLICED P53 - BINDING TO DNA AND INTERACTION WITH THE MAJOR P53 PROTEIN IN-VITRO AND IN CELLS
    WU, Y
    LIU, YG
    LEE, L
    MINER, Z
    KULESZMARTIN, M
    EMBO JOURNAL, 1994, 13 (20): : 4823 - 4830
  • [26] Adenoviral-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer
    Bouvet, M
    Bold, RJ
    Fang, B
    Evans, DB
    Abbruzzese, JL
    Chiao, PJ
    Chandra, J
    McConkey, DJ
    Roth, JA
    CANCER GENE THERAPY, 1997, 4 (06) : P26 - P26
  • [27] Wild-type p53 controls the level of fibronectin expression in breast cancer cells
    You, Daeun
    Jung, Seung Pil
    Jeong, Yisun
    Bae, Soo Youn
    Kim, Sangmin
    ONCOLOGY REPORTS, 2017, 38 (04) : 2551 - 2557
  • [28] Nuclear inclusion bodies of mutant and wild-type p53 in cancer: a hallmark of p53 inactivation and proteostasis remodelling by p53 aggregation
    De Smet, Frederik
    Rubio, Mirian Saiz
    Hompes, Daphne
    Naus, Evelyne
    De Baets, Greet
    Langenberg, Tobias
    Hipp, Mark S.
    Houben, Bert
    Claes, Filip
    Charbonneau, Sarah
    Blanco, Javier Delgado
    Plaisance, Stephane
    Ramkissoon, Shakti
    Ramkissoon, Lori
    Simons, Colinda
    van den Brandt, Piet
    Weijenberg, Matty
    Van England, Manon
    Lambrechts, Sandrina
    Amant, Frederic
    D'Hoore, Andre
    Ligon, Keith L.
    Sagaert, Xavier
    Schymkowitz, Joost
    Rousseau, Frederic
    JOURNAL OF PATHOLOGY, 2017, 242 (01): : 24 - 38
  • [29] COTRANSLATION OF ACTIVATED MUTANT P53 WITH WILD-TYPE DRIVES THE WILD-TYPE P53 PROTEIN INTO THE MUTANT CONFORMATION
    MILNER, J
    MEDCALF, EA
    CELL, 1991, 65 (05) : 765 - 774
  • [30] Enhancement of radiosensitivity of wild-type p53 human glioma cells by adenovirus-mediated delivery of the p53 gene
    Lang, FF
    Yung, WKA
    Raju, U
    Libunao, F
    Terry, NHA
    Tofilon, PJ
    JOURNAL OF NEUROSURGERY, 1998, 89 (01) : 125 - 132